Acrux Limited (AU:ACR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Acrux Limited has announced the commercial launch of its Nitroglycerin 0.4% ointment in the US market through its licensee, TruPharma, following FDA approval. The company is also offering a Share Purchase Plan to raise up to $2 million, available to eligible shareholders in Australia and New Zealand until December 18, 2024. With a strong track record in topical pharmaceuticals, Acrux continues to expand its product offerings globally.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
